162 related articles for article (PubMed ID: 24695996)
1. The early course of affective and cognitive symptoms in de novo patients with Parkinson's disease.
Spalletta G; Robinson RG; Cravello L; Pontieri FE; Pierantozzi M; Stefani A; Long JD; Caltagirone C; Assogna F
J Neurol; 2014 Jun; 261(6):1126-32. PubMed ID: 24695996
[TBL] [Abstract][Full Text] [Related]
2. Neuropsychiatric and cognitive symptoms and body side of onset of parkinsonism in unmedicated Parkinson's disease patients.
Pellicano C; Assogna F; Cravello L; Langella R; Caltagirone C; Spalletta G; Pontieri FE
Parkinsonism Relat Disord; 2015 Sep; 21(9):1096-100. PubMed ID: 26173702
[TBL] [Abstract][Full Text] [Related]
3. Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients.
Kulisevsky J; García-Sánchez C; Berthier ML; Barbanoj M; Pascual-Sedano B; Gironell A; Estévez-González A
Mov Disord; 2000 Jul; 15(4):613-26. PubMed ID: 10928571
[TBL] [Abstract][Full Text] [Related]
4. Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study).
Reid WG; Hely MA; Morris JG; Loy C; Halliday GM
J Neurol Neurosurg Psychiatry; 2011 Sep; 82(9):1033-7. PubMed ID: 21335570
[TBL] [Abstract][Full Text] [Related]
5. Paradoxical effect of dopamine medication on cognition in Parkinson's disease: relationship to side of motor onset.
Hanna-Pladdy B; Pahwa R; Lyons KE
J Int Neuropsychol Soc; 2015 Apr; 21(4):259-70. PubMed ID: 25923830
[TBL] [Abstract][Full Text] [Related]
6. [An impact of pronoran on cognitive and affective disorders in Parkinson's disease].
Pilipovich AA; Golubev VL
Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(4):41-7. PubMed ID: 15875942
[TBL] [Abstract][Full Text] [Related]
7. Long-term cognitive follow-up of Parkinson's disease patients with impulse control disorders.
Siri C; Cilia R; Reali E; Pozzi B; Cereda E; Colombo A; Meucci N; Canesi M; Zecchinelli AL; Tesei S; Mariani CB; Sacilotto G; Zini M; Pezzoli G
Mov Disord; 2015 Apr; 30(5):696-704. PubMed ID: 25757654
[TBL] [Abstract][Full Text] [Related]
8. Sociodemographic, neuropsychiatric and cognitive characteristics of pathological gambling and impulse control disorders NOS in Parkinson's disease.
Pontieri FE; Assogna F; Pellicano C; Cacciari C; Pannunzi S; Morrone A; Danese E; Caltagirone C; Spalletta G
Eur Neuropsychopharmacol; 2015 Jan; 25(1):69-76. PubMed ID: 25435085
[TBL] [Abstract][Full Text] [Related]
9. Differences between the behavioral and psychological symptoms of Alzheimer's disease and Parkinson's disease.
Tokuchi R; Hishikawa N; Sato K; Hatanaka N; Fukui Y; Takemoto M; Ohta Y; Yamashita T; Abe K
J Neurol Sci; 2016 Oct; 369():278-282. PubMed ID: 27653908
[TBL] [Abstract][Full Text] [Related]
10. Early-stage cognitive impairment in Parkinson's disease and the influence of dopamine replacement therapy.
Miah IP; Olde Dubbelink KT; Stoffers D; Deijen JB; Berendse HW
Eur J Neurol; 2012 Mar; 19(3):510-6. PubMed ID: 22040383
[TBL] [Abstract][Full Text] [Related]
11. [Motor, cognitive and affective disorders in Parkinson's disease].
Vendrova MI; Golubev VL; Sadekov RA; Veĭn AM
Zh Nevrol Psikhiatr Im S S Korsakova; 2003; 103(3):13-7. PubMed ID: 12830500
[TBL] [Abstract][Full Text] [Related]
12. Greater intraindividual variability in neuropsychological performance predicts cognitive impairment in de novo Parkinson's disease.
Jones JD; Burroughs M; Apodaca M; Bunch J
Neuropsychology; 2020 Jan; 34(1):24-30. PubMed ID: 31219297
[TBL] [Abstract][Full Text] [Related]
13. Gender differences on motor and non-motor symptoms of de novo patients with early Parkinson's disease.
Song Y; Gu Z; An J; Chan P;
Neurol Sci; 2014 Dec; 35(12):1991-6. PubMed ID: 25012756
[TBL] [Abstract][Full Text] [Related]
14. A registry-based, case-control investigation of Parkinson's disease with and without cognitive impairment.
Papapetropoulos S; Ellul J; Polychronopoulos P; Chroni E
Eur J Neurol; 2004 May; 11(5):347-51. PubMed ID: 15142230
[TBL] [Abstract][Full Text] [Related]
15. Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson's disease patients.
Pellecchia MT; Santangelo G; Picillo M; Pivonello R; Longo K; Pivonello C; Vitale C; Amboni M; De Rosa A; Moccia M; Erro R; De Michele G; Santoro L; Colao A; Barone P
J Neurol; 2013 Feb; 260(2):438-44. PubMed ID: 22911513
[TBL] [Abstract][Full Text] [Related]
16. Link between non-motor symptoms and cognitive dysfunctions in de novo, drug-naive PD patients.
Erro R; Santangelo G; Picillo M; Vitale C; Amboni M; Longo K; Costagliola A; Pellecchia MT; Allocca R; De Rosa A; De Michele G; Santoro L; Barone P
J Neurol; 2012 Sep; 259(9):1808-13. PubMed ID: 22310940
[TBL] [Abstract][Full Text] [Related]
17. The heterogeneity of non-motor symptoms of Parkinson's disease.
Zhang N; Liu W; Ye M; Cohen AD; Zhang Y
Neurol Sci; 2015 Apr; 36(4):577-84. PubMed ID: 25376559
[TBL] [Abstract][Full Text] [Related]
18. Cognitive impairment is associated with Hoehn and Yahr stages in early, de novo Parkinson disease patients.
Siciliano M; De Micco R; Trojano L; De Stefano M; Baiano C; Passaniti C; De Mase A; Russo A; Tedeschi G; Tessitore A
Parkinsonism Relat Disord; 2017 Aug; 41():86-91. PubMed ID: 28576605
[TBL] [Abstract][Full Text] [Related]
19. Dopaminergic Effect on Non-Motor Symptoms in Late Stage Parkinson's Disease.
Rosqvist K; Odin P; Hagell P; Iwarsson S; Nilsson MH; Storch A
J Parkinsons Dis; 2018; 8(3):409-420. PubMed ID: 30056433
[TBL] [Abstract][Full Text] [Related]
20. Cognitive decline in early Parkinson's disease.
Kandiah N; Narasimhalu K; Lau PN; Seah SH; Au WL; Tan LC
Mov Disord; 2009 Mar; 24(4):605-8. PubMed ID: 19191342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
